Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

ObjectivesMore and more encouraging evidence revealed that immunotherapy could improve clinical outcomes in patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) variations. However, immunotherapy is still a controversy for NSCLC patients wi...

Full description

Bibliographic Details
Main Authors: Ya Chen, Zhengyu Yang, Yanan Wang, Minjuan Hu, Bo Zhang, Yanwei Zhang, Fangfei Qian, Wei Zhang, Baohui Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
pembrolizumab
epidermal growth factor receptor
antiangiogenic agent
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.671228/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.671228/full

Similar Items